2417-75-6

Usage

1-Naphthalenecarboxylic acid, 4-(bromomethyl)-, methyl ester is a chemical compound with the following properties and specific content

1-Naphthalenecarboxylic acid, 4-(bromomethyl)-, methyl ester consists of 13 carbon atoms, 11 hydrogen atoms, 1 bromine atom, and 2 oxygen atoms.

Methyl ester derivative

4-(bromomethyl)naphthalene carboxylic acid
It is derived from 4-(bromomethyl)naphthalene carboxylic acid by replacing the carboxyl group (-COOH) with a methyl ester group (-COOCH3).

Uses in organic synthesis

It serves as an intermediate compound in the synthesis of various organic compounds.

Building block in pharmaceuticals, dyes, and agrochemicals production

1-Naphthalenecarboxylic acid, 4-(bromomethyl)-, methyl ester is commonly used as a starting material or building block in the production of pharmaceuticals, dyes, and agrochemicals due to its reactive functional groups and structural features.

Research and development applications

It is utilized in research and development for its potential applications in the fields of medicine and materials science, such as drug design and development, or the creation of new materials with unique properties.

Hazardous nature

1-Naphthalenecarboxylic acid, 4-(bromomethyl)-, methyl ester is considered hazardous, and it is important to handle it with care and follow proper safety precautions when working with it. This may include wearing appropriate personal protective equipment, working in a well-ventilated area, and following established laboratory safety protocols.

Upstream product

• 4488-40-8 4-Methyl-1-naphthoic acid 
• 90-12-0 1-Methylnaphthalene 
• 28418-86-2 1-acetyl-4-methylnaphthalene 
• 186581-53-3 diazomethane 
• 30236-02-3 4-(bromomethyl)-naphthalene-1-carboxylic acid 
• 35615-98-6 methyl 4-methyl-1-naphthalenecarboxylate 
• 34241-39-9 azobisisobutyronitrile 
• 67-56-1 methanol 
• 79996-84-2 4-methoxymethyl-1-naphthoic acid 
• 79996-79-5 1-acetyl-4-methoxymethylnaphthalene 
• 79996-80-8 1-acetyl-4-bromomethylnaphthalene 

Downstream Products

• 1367282-60-7 (Z)-4-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(2-(isopropoxyimino)ethyl)-1-naphthamide 
• 1367282-58-3 (E)-4-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(2-(isopropoxyimino)ethyl)-1-naphthamide 
• 35615-98-6 methyl 4-methyl-1-naphthalenecarboxylate 

Relevant academic research and scientific papers

Method for preparing oxazoline insecticide arforaging intermediate

The invention discloses a method for preparing an oxazoline insecticide arfamarin intermediate. The intermediate is 4-formyl-naphthalene-1-carboxylic acid, and compared with a synthesis route of US6613942B1, the synthesis route of the oxazoline insecticide arfamarin is simple. According to the method provided by some embodiments of the invention, through exploration, the reaction steps are shortened from three steps to one step, so the oxazoline insecticide arforlaana intermediate product with qualified purity can be obtained. The intermediate control steps are simplified, meanwhile, the product yield is increased, and industrial production is easier.

Palladium-Catalyzed Regiospecific peri- And ortho-C-H Oxygenations of Polyaromatic Rings Mediated by Tunable Directing Groups

An efficient divergent approach of Pd-catalyzed C-H oxygenation of polyaromatic rings is described. Reversible directing groups enable regiospecific peri- and ortho-oxygenation to readily access a wide array of polyaromatic phenols without pre- and postmanipulation of directing groups. The systematic mechanistic investigation, including deuterium-labeling experiments, palladacycle trapping, and DFT calculations, reveals that the tunable ligand-assisted C-H bond cleavage played a crucial role during the reaction process.

ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS

This invention recites naphthyl isoxazoline oxime derivatives of Formula (1) geometric isomers, stereoisomers thereof, pharmaceutically or veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in animals. The variables, R1a, R1b, R1c, R2, R3, and are as described herein.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

FXR AGONISTS

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

AMINE COMPOUNDS AND USE THEREOF

It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(=O) or NR11; and D is a group represented by the following general formula (4) or (6).-Q-Y-BIn the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND

To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism. Nitrogen-containing compounds represented by the following general formula and

NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME

The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.

Synthesis and biological activity of new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase inhibitors: 2-oxetanones with a side chain mimicking the folded structure of 1233A.

To mimic the folded side chain conformation of 1233A (1), which is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase inhibitor, 1233A analogs with aromatic rings in the side chain were synthesized. The 2-oxetanone moiety was kept intact. Among 1233A and its synthetic analogs, trans-3-hydroxymethyl-4-[2-(7-methoxycarbonyl-1-naphthyl)ethyl]-2-oxe tanone (23) showed the highest HMG-CoA synthase inhibitory activity in vitro. The structure-activity relationship at the side chain is discussed.

SUBSTITUTED IMIDAZOLES HAVING ANGIOTENSIN II RECEPTOR BLOCKING ACTIVITY

Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of